Empirical Asset Management, LLC Incyte Corp Transaction History

Empirical Asset Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 31, 2023	SELL	$67.18 - $84.11 $88,072 - $110,268	-1,311 Reduced 16.74%	6,519 $523,000
Q3 2022 Oct 19, 2022	BUY	$66.18 - $82.86 $16,147 - $20,217	244 Added 3.22%	7,830 $522,000
Q2 2022 Jul 18, 2022	BUY	$66.18 - $83.18 $33,619 - $42,255	508 Added 7.18%	7,586 $576,000
Q1 2022 May 06, 2022	BUY	$66.02 - $79.71 $467,289 - $564,187	7,078 New	7,078 $562,000

642

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.8B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Empirical Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Empirical Asset Management, LLC with notifications on news.